Originally published as JCO Early Release 10.1200/JCO.2007.11.3886 on September 24 2007

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jordan, V. C. Articles by O'Malley, B. W. Search for Related Content PubMed PubMed Citation Articles by Jordan, V. C. Articles by O'Malley, B. W. Social Bookmarking                            What's this?

Selective Estrogen-Receptor Modulators and Antihormonal Resistance in Breast Cancer

V. Craig Jordan, Bert W. O'Malley

From the Fox Chase Cancer Center, Philadelphia, PA; and Baylor College of Medicine, Houston, TX

Address reprint requests to V. Craig Jordan, OBE, PhD, DSc, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111-2497; e-mail: v.craig.jordan{at}fccc.edu

Selective estrogen-receptor (ER) modulators (SERMs) are synthetic nonsteroidal compounds that switch on and switch off target sites throughout the body. Tamoxifen, the pioneering SERM, blocks estrogen action by binding to the ER in breast cancers. Tamoxifen has been used ubiquitously in clinical practice during the last 30 years for the treatment of breast cancer and is currently available to reduce the risk of breast cancer in high-risk women. Raloxifene maintains bone density (estrogen-like effect) in postmenopausal osteoporotic women, but at the same time reduces the incidence of breast cancer in both high- and low-risk (osteoporotic) postmenopausal women. Unlike tamoxifen, raloxifene does not increase the incidence of endometrial cancer. Clearly, the simple ER model of estrogen action can no longer be used to explain SERM action at different sites around the body. Instead, a new model has evolved on the basis of the discovery of protein partners that modulate estrogen action at distinct target sites. Coactivators are the principal players that assemble a complex of functional proteins around the ligand ER complex to initiate transcription of a target gene at its promoter site. A promiscuous SERM ER complex creates a stimulatory signal in growth factor receptor–rich breast or endometrial cancer cells. These events cause drug-resistant, SERM-stimulated growth. The sometimes surprising pharmacology of SERMs has resulted in a growing interest in the development of new selective medicines for other members of the nuclear receptor superfamily. This will allow the precise treatment of diseases that was previously considered impossible.

published online ahead of print at www.jco.org on September 24, 2007.

Supported by the Department of Defense Breast Program under award number BC050277 Center of Excellence, SPORE in Breast Cancer CA 89018, R01 GM067156, FCCC Core Grant, NIH P30 CA006927, the Avon Foundation, and the Weg Fund of Fox Chase Cancer Center (V.J.C.); and National Institute of Health grants from the National Institute of Child Health and Human Development and National Institute of Diabetes and Digestive and Kidney Diseases, and Nuclear Receptor Signaling Atlas (B.W.O.).

Views and opinions of, and endorsements by the author(s) do not reflect those of the US Army or the Department of Defense.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. C. Lin, M. Suzawa, R. D. Blind, S. C. Tobias, S. E. Bulun, T. S. Scanlan, and H. A. Ingraham Stimulating the GPR30 Estrogen Receptor with a Novel Tamoxifen Analogue Activates SF-1 and Promotes Endometrial Cell Proliferation Cancer Res., July 1, 2009; 69(13): 5415 - 5423. [Abstract] [Full Text] [PDF]

				R. Kumar, H. Zhang, C. Holm, R. K. Vadlamudi, G. Landberg, and S. K. Rayala Extranuclear Coactivator Signaling Confers Insensitivity to Tamoxifen Clin. Cancer Res., June 15, 2009; 15(12): 4123 - 4130. [Abstract] [Full Text] [PDF]

				P. Bhat-Nakshatri, G. Wang, N. R. Collins, M. J. Thomson, T. R. Geistlinger, J. S. Carroll, M. Brown, S. Hammond, E. F. Srour, Y. Liu, et al. Estradiol-regulated microRNAs control estradiol response in breast cancer cells Nucleic Acids Res., June 14, 2009; (2009) gkp500v1. [Abstract] [Full Text] [PDF]

				M. J. Chisamore, H. A. Wilkinson, O. Flores, and J. D. Chen Estrogen-related receptor-{alpha} antagonist inhibits both estrogen receptor-positive and estrogen receptor-negative breast tumor growth in mouse xenografts Mol. Cancer Ther., March 1, 2009; 8(3): 672 - 681. [Abstract] [Full Text] [PDF]

				V. C. Jordan A Century of Deciphering the Control Mechanisms of Sex Steroid Action in Breast and Prostate Cancer: The Origins of Targeted Therapy and Chemoprevention Cancer Res., February 15, 2009; 69(4): 1243 - 1254. [Abstract] [Full Text] [PDF]

				P. Bhat-Nakshatri, G. Wang, H. Appaiah, N. Luktuke, J. S. Carroll, T. R. Geistlinger, M. Brown, S. Badve, Y. Liu, and H. Nakshatri AKT Alters Genome-Wide Estrogen Receptor {alpha} Binding and Impacts Estrogen Signaling in Breast Cancer Mol. Cell. Biol., December 15, 2008; 28(24): 7487 - 7503. [Abstract] [Full Text] [PDF]

				A. Thomsen and J. M. Kolesar Chemoprevention of breast cancer Am. J. Health Syst. Pharm., December 1, 2008; 65(23): 2221 - 2228. [Abstract] [Full Text] [PDF]

				D. J Kojetin, T. P Burris, E. V Jensen, and S. A Khan Implications of the binding of tamoxifen to the coactivator recognition site of the estrogen receptor Endocr. Relat. Cancer, December 1, 2008; 15(4): 851 - 870. [Abstract] [Full Text] [PDF]

				M. Rokavec, W. Schroth, S. M.C. Amaral, P. Fritz, L. Antoniadou, D. Glavac, W. Simon, M. Schwab, M. Eichelbaum, and H. Brauch A Polymorphism in the TC21 Promoter Associates with an Unfavorable Tamoxifen Treatment Outcome in Breast Cancer Cancer Res., December 1, 2008; 68(23): 9799 - 9808. [Abstract] [Full Text] [PDF]

				O. Khalid, S. K. Baniwal, D. J. Purcell, N. Leclerc, Y. Gabet, M. R. Stallcup, G. A. Coetzee, and B. Frenkel Modulation of Runx2 Activity by Estrogen Receptor-{alpha}: Implications for Osteoporosis and Breast Cancer Endocrinology, December 1, 2008; 149(12): 5984 - 5995. [Abstract] [Full Text] [PDF]

				V. C. Jordan The 38th David A. Karnofsky Lecture: The Paradoxical Actions of Estrogen in Breast Cancer--Survival or Death? J. Clin. Oncol., June 20, 2008; 26(18): 3073 - 3082. [Abstract] [Full Text] [PDF]